ZVRA Stock Analysis: Zevra Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 826m USD | 12M Return: 28.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 22.4M
Qual. Beats: 0
Rev. Trend: 94.2%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Zevra Therapeutics (NASDAQ: ZVRA) is a U.S.-based, commercial-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases, leveraging its proprietary Ligand Activated Technology (LAT) platform to advance its pipeline. The companys lead clinical candidate, KP1077, is being evaluated in Phase 3 trials for both idiopathic hypersomnia (KP1077IH) and narcolepsy (KP1077N), while Celiprolol is in Phase 3 development for vascular Ehlers-Danlos syndrome. Zevra markets three approved products: AZSTARYS, a once-daily ADHD therapy for patients aged six and older; OLPRUVA, a treatment for urea cycle disorders; and MIPLYFFA, approved for Niemann-Pick disease type C, an ultra-rare neurodegenerative disorder. The company, formerly known as KemPharm before rebranding in February 2023, supports its development activities through collaboration and license agreements with partners including Commave Therapeutics, Acer, and Relief Therapeutics, and is headquartered in Boston, Massachusetts. As a small-cap biotechnology firm operating in the rare disease space, Zevras business model combines revenue from its small portfolio of approved specialty therapies with longer-term value creation from late-stage clinical candidates targeting underserved patient populations with limited treatment options.
- KP1077 Phase 3 data in idiopathic hypersomnia and narcolepsy
- AZSTARYS ADHD prescription growth drives commercial revenue
- MIPLYFFA launch trajectory in Niemann-Pick type C
- Cash runway and capital allocation amid small-cap burn
| Net Income: 124.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 40.10 > 1.0 |
| NWC/Revenue: 149.6% < 20% (prev 134.5%; Δ 15.08% < -1%) |
| CFO/TA 0.05 > 3% & CFO 12.8m > Net Income 124.2m |
| Net Debt (-32.1m) to EBITDA (140.5m): -0.23 < 3 |
| Current Ratio: 4.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (60.2m) vs 12m ago 11.34% < -2% |
| Gross Margin: 85.51% > 18% (prev 78.84%; Δ 6.67% > 0.5%) |
| Asset Turnover: 54.20% > 50% (prev 23.50%; Δ 30.69% > 0%) |
| Interest Coverage Ratio: 17.84 > 6 (EBIT TTM 137.7m / Interest Expense TTM 7.72m) |
| A: 0.66 (Total Current Assets 230.0m - Total Current Liabilities 47.0m) / Total Assets 278.6m |
| B: -1.38 (Retained Earnings -384.2m / Total Assets 278.6m) |
| C: 0.61 (EBIT TTM 137.7m / Avg Total Assets 225.6m) |
| D: 2.83 (Book Value of Equity 205.8m / Total Liabilities 72.8m) |
| Altman-Z'' = 6.88 = AAA |
| DSRI: 0.58 (Receivables 22.1m/12.6m, Revenue 122.3m/40.6m) |
| GMI: 0.92 (GM 78.84% / 85.51%) |
| AQI: 0.33 (AQ_t 0.17 / AQ_t-1 0.52) |
| SGI: 3.01 (Revenue 122.3m / 40.6m) |
| TATA: 0.40 (NI 124.2m - CFO 12.8m) / TA 278.6m) |
| Beneish M = -2.35 (Cap -4..+1) = BBB |
As of July 08, 2026, the stock is trading at USD 14.44 with a total of 1,875,633 shares traded. Over the past week, the price has changed by +3.07%, over one month by +19.44%, over three months by +49.17% and over the past year by +28.13%.
Current recommended Stop Loss: 13.60 (which is 5.8% or 1.3 ATR below the current price).
Zevra Therapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy ZVRA.
- StrongBuy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.9 | 93.1% |
P/E Trailing = 6.9552
P/E Forward = 12.9032
P/S = 6.758
P/B = 3.9668
P/EG = 10.6667
Revenue TTM = 122.3m USD
EBIT TTM = 137.7m USD
EBITDA TTM = 140.5m USD
Long Term Debt = 61.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 406k USD (from shortTermDebt, last quarter)
Debt = 63.5m USD (corrected: LT Debt 61.9m + ST Debt 406k) + Leases 1.15m
Net Debt = -32.1m USD (calculated: Debt 63.5m - CCE 95.6m)
Enterprise Value = 794.3m USD (826.4m + Debt 63.5m - CCE 95.6m)
Interest Coverage Ratio = 17.84 (Ebit TTM 137.7m / Interest Expense TTM 7.72m)
EV/FCF = 66.22x (Enterprise Value 794.3m / FCF TTM 12.0m)
FCF Yield = 1.51% (FCF TTM 12.0m / Enterprise Value 794.3m)
FCF Margin = 9.81% (FCF TTM 12.0m / Revenue TTM 122.3m)
Net Margin = 101.6% (Net Income TTM 124.2m / Revenue TTM 122.3m)
Gross Margin = 85.51% ((Revenue TTM 122.3m - Cost of Revenue TTM 17.7m) / Revenue TTM)
Gross Margin QoQ = 93.75% (prev none%)
Tobins Q-Ratio = 2.85 (Enterprise Value 794.3m / Total Assets 278.6m)
Interest Expense / Debt = 12.16% (Interest Expense 7.72m / Debt 63.5m)
Taxrate = 6.88% (9.18m / 133.4m)
NOPAT = 128.2m (EBIT 137.7m * (1 - 6.88%))
Current Ratio = 4.89 (Total Current Assets 230.0m / Total Current Liabilities 47.0m)
Debt / Equity = 0.31 (Debt 63.5m / totalStockholderEquity, last quarter 205.8m)
Debt / EBITDA = -0.23 (Net Debt -32.1m / EBITDA 140.5m)
Debt / FCF = -2.68 (Net Debt -32.1m / FCF TTM 12.0m)
Total Stockholder Equity = 152.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 55.05% (Net Income 124.2m / Total Assets 278.6m)
RoE = 81.34% (Net Income TTM 124.2m / Total Stockholder Equity 152.7m)
RoCE = 64.15% (EBIT 137.7m / Capital Employed (Equity 152.7m + L.T.Debt 61.9m))
RoIC = 56.77% (NOPAT 128.2m / Invested Capital 225.8m)
WACC = 6.30% (E(826.4m)/V(889.9m) * Re(5.91%) + D(63.5m)/V(889.9m) * Rd(12.16%) * (1-Tc(0.07)))
Discount Rate = 5.91% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 17.96%
[DCF] Terminal Value 75.44% ; FCFF base≈12.0m ; Y1≈12.0m ; Y5≈12.8m
[DCF] Fair Price = 3.90 (EV 198.4m - Net Debt -32.1m = Equity 230.6m / Shares 59.1m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.19 | # QB: 0
Revenue Correlation: 94.24 | Revenue CAGR: 147.2% | SUE: 1.61 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.16 | Chg30d=-3.03% | Revisions=-40% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.18 | Chg30d=-10.13% | Revisions=-25% | Analysts=4
EPS current Year (2026-12-31): EPS=1.22 | Chg30d=+5.00% | Revisions=+25% | GrowthEPS=-9.4% | GrowthRev=+36.9%
EPS next Year (2027-12-31): EPS=1.20 | Chg30d=-37.60% | Revisions=-40% | GrowthEPS=-2.3% | GrowthRev=+25.1%
[Analyst] Revisions Ratio: -44% (up=1, down=5)